Related Experiment Videos
Atopic Dermatitis: New Targets and Emerging Systemic Therapies
Gianluca Avallone1,2,3, Jessica Beaziz1, Flavia Manzo Margiotta1,4,5
1Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
American Journal of Clinical Dermatology
|June 29, 2026
Summary
New biologic and small-molecule therapies are advancing atopic dermatitis (AD) treatment. These innovations aim for better efficacy and safety, addressing unmet needs in managing this chronic inflammatory skin condition.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin disease impacting quality of life.
- Current treatments, including biologics and small molecules, have improved outcomes but face challenges in achieving complete, durable clearance and long-term safety.
- Unmet needs in AD management drive innovation in therapeutic strategies.
Purpose of the Study:
- To review current translational and clinical advances in the atopic dermatitis therapeutic pipeline.
- To highlight novel approaches for modulating established pathways and identifying new targets for AD management.
Main Methods:
- Review of next-generation biologics with enhanced antibody engineering for improved efficacy and dosing.
- Evaluation of bispecific and multispecific antibodies for synergistic immunomodulatory effects.
- Analysis of T-cell rebalancing strategies and emerging oral small-molecule inhibitors of intracellular signaling.
Main Results:
- Next-generation biologics aim for enhanced efficacy and extended dosing intervals.
- Bispecific/multispecific antibodies offer potential synergistic effects in inflammatory skin diseases.
- T-cell rebalancing strategies show durable off-treatment responses, and oral small molecules exhibit favorable early-phase safety profiles.
Conclusions:
- The evolving therapeutic landscape for atopic dermatitis includes refined biologics, novel multi-target antibodies, T-cell modulation, and oral small molecules.
- These advancements hold promise for transforming the future management of AD by addressing current limitations and unmet needs.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:27Acne Infection
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include: